Effects of Hormone and Carb Treatment
The Peter Attia Drive
View the Show Notes Page for This Episode Become a...
more
Dec 4 2023 2h 23m
Chapter 1 7 mins
An overview of the Interventions Testing Program (ITP)Chapter 2 7 mins
How the mice used by the ITP are superior for research relative to mouse models used in most researchChapter 3 10 mins
Design of ITP studies, outcomes tested, and metrics of interestChapter 4 6 mins
The process and challenges of drug formulation for miceChapter 5 6 mins
Four drugs identified by the ITP that extends the lifespan of miceChapter 6 7 mins
The success of rapamycin and what it tells us about the biology of agingChapter 7 6 mins
Other measures of healthspan evaluated by the ITP in stage 2 studiesChapter 8 1 min
Distinguishing aging rate indicators from biomarkers of agingChapter 9 12 mins
Aging rate indicators identified through the examination of slow-aging miceChapter 10 9 mins
Why proteomics are essential to understand changes in the cellChapter 11 5 mins
Unraveling aging rate indicators: dose-effect, duration, and future frontiersChapter 12 11 mins
A closer look at aging rate indicators: bridging the gap from mice to humansChapter 13 3 mins
What do laboratory mice die from?Chapter 14 1 min
Distinguishing between a drug that improves an age-sensitive outcome and a drug that improves all aspects of agingChapter 15 7 mins
The ITP study of 17⍺-estradiol: mechanisms of life extension and surprising sex differencesChapter 16 9 mins
Unsuccessful drugs studied by the ITP: resveratrol, metformin, and nicotinamide ribosideChapter 17 5 mins
Over-the-counter successes in the ITP: meclizine and astaxanthinChapter 18 5 mins
A senolytic drug, fisetin, fails to extend lifespanChapter 19 3 mins
Can targeting senescent cells slow aging?Chapter 20 7 mins
and